At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LENZ Therapeutics
Post-Mkt 12-08 16:31:15 EST
26.71
-0.01
-0.04%
盘后26.71
+0.000.00%
16:10 EST
High27.84Low26.03Vol726.24K
Open26.94D1 Closing26.72Amplitude6.77%
Mkt Cap835.76MTradable Cap419.15MTotal Shares31.29M
T/O19.44MT/O Rate4.63%Tradable Shares15.69M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Structure Therapeutics Plans $500 Million Public Offering
MT Newswires Live  ·  16 minutes ago
Structure Therapeutics Plans $500 Million Public Offering
Structure Therapeutics Shares Surge on Positive Phase 2b Results for Obesity Drug Aleniglipron
MT Newswires Live  ·  12-08 23:47
Structure Therapeutics Shares Surge on Positive Phase 2b Results for Obesity Drug Aleniglipron
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
GlobeNewswire  ·  12-08 21:35
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer
GlobeNewswire  ·  12-08 21:30
Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer
Atossa Therapeutics Is Maintained at Buy by Ascendiant Capital
Dow Jones  ·  12-08 18:45
Atossa Therapeutics Is Maintained at Buy by Ascendiant Capital
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
GlobeNewswire  ·  12-08 07:20
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
GlobeNewswire  ·  12-07 06:30
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
GlobeNewswire  ·  12-06 21:00
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting
Spyre Therapeutics Announces Grants of Inducement Awards
GlobeNewswire  ·  12-06
Spyre Therapeutics Announces Grants of Inducement Awards
Wedbush Adjusts Denali Therapeutics Price Target to $31 From $30, Maintains Outperform Rating
MT Newswires Live  ·  12-05
Wedbush Adjusts Denali Therapeutics Price Target to $31 From $30, Maintains Outperform Rating
Neuphoria Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  12-05
Neuphoria Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Morgan Stanley Initiates BridgeBio Oncology Therapeutics With Overweight Rating, $20 Price Target
MT Newswires Live  ·  12-05
Morgan Stanley Initiates BridgeBio Oncology Therapeutics With Overweight Rating, $20 Price Target
Denali Therapeutics Price Target Maintained With a $32.00/Share by BTIG
Dow Jones  ·  12-05
Denali Therapeutics Price Target Maintained With a $32.00/Share by BTIG
Press Release: OTR Therapeutics Raises $100 Million in Series A Financing to Advance Early Innovation into Global Transformative Therapies
Dow Jones  ·  12-05
Press Release: OTR Therapeutics Raises $100 Million in Series A Financing to Advance Early Innovation into Global Transformative Therapies
Enliven Therapeutics (ELVN): Assessing Valuation After a Recent 13% Share Price Rebound
Simply Wall St.  ·  12-05
Enliven Therapeutics (ELVN): Assessing Valuation After a Recent 13% Share Price Rebound
Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia
GlobeNewswire  ·  12-05
Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia
Protara Therapeutics Launches Offering of Securities
MT Newswires Live  ·  12-05
Protara Therapeutics Launches Offering of Securities
Press Release: Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
Dow Jones  ·  12-04
Press Release: Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
Denali Therapeutics, Royalty Pharma Enter $275 Million Royalty Funding Agreement for Hunter Syndrome Treatment
Dow Jones  ·  12-04
Denali Therapeutics, Royalty Pharma Enter $275 Million Royalty Funding Agreement for Hunter Syndrome Treatment
Trevi Therapeutics Names David Hastings CFO
MT Newswires Live  ·  12-04
Trevi Therapeutics Names David Hastings CFO

Introduction

Company Name.
Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Issue price:
--